Skip to main content

Table 5 Univariate analyses and Multivariate analyses for overall survival in patients with endometrial carcinoma about clinicopathological features and mesothelin, CA125 expressions

From: Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis

Variables   Univariate analysis Multivariate analysis for mesothelin expression Multivariate analysis for co-expression of mesothelin and CA125
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age ≥ 60 vs. <  60 2.01 (1.23–3.35) < 0.01 1.56 (0.91–2.70) 0.10 1.55 (0.91–2.70) 0.10
Histological type Grade 2 endometrioid carcinoma vs. Grade 1 endometrioid carcinoma 2.92 (1.36–6.39) < 0.01 1.46 (0.63–3.42) 0.36 1.47 (0.63–3.45) 0.36
  Grade 3 endometrioid carcinoma vs. Grade 1 endometrioid carcinoma 5.30 (2.46–11.6) < 0.01 3.68 (1.58–8.78) < 0.01 3.70 (1.58–8.82) < 0.01
  Other carcinomas vs. Grade 1 endometrioid carcinoma 8.22 (4.22–17.0) < 0.01 2.97 (1.34–6.87) < 0.01 2.99 (1.35–6.91) < 0.01
FIGO stage III.IV vs. I.II 7.05 (4.35–11.6) < 0.01 1.62 (0.64–3.98) 0.29 1.61 (0.64–3.95) 0.30
Depth of myometrial invasion ≥1/2 vs. < 1/2 3.59 (2.22–5.92) < 0.01 1.47 (0.78–2.80) 0.23 1.45 (0.77–2.78) 0.24
Lymphovascular invasion Yes vs. no 3.96 (2.37–6.87) < 0.01 2.47 (1.25–4.90) < 0.01 2.46 (1.25–4.89) < 0.01
Cervical invasion Yes vs. no 2.11 (1.25–3.46) < 0.01 1.34 (0.73–2.40) 0.33 1.34 (0.73–2.41) 0.33
Ovarian metastasis Yes vs. no 10.3 (5.95–17.3) < 0.01 1.75 (0.86–3.57) 0.12 1.75 (0.86–3.57) 0.12
Lymph node metastasis Yes vs. no 4.50 (2.47–8.04) < 0.01 1.15 (0.52–2.62) 0.72 1.15 (0.51–2.61) 0.72
  Yes vs. unevaluated 1.09 (0.58–2.01) 0.77 0.92 (0.43–1.97) 0.84 0.92 (0.43–1.97) 0.84
  Unevaluated vs. no 4.11 (2.34–7.15) < 0.01 1.24 (0.62–2.44) 0.52 1.24 (0.62–2.43) 0.53
Distant metastasis Yes vs. no 13.8 (8.14–22.8) < 0.01 5.47 (2.45–12.4) < 0.01 5.45 (2.44–12.4) < 0.01
Peritoneal cytology Positive vs. negative 5.18 (3.20–8.36) < 0.01 1.93 (1.01–3.66) 0.046 1.92 (1.00–3.65) 0.047
Adjuvant therapy Yes vs. no 2.00 (1.20–3.43) < 0.01 0.26 (0.12–0.54) < 0.01 0.26 (0.12–0.54) < 0.01
Mesothelin expression Yes vs. no 3.14 (1.95–5.13) < 0.01 2.18 (1.31–3.71) < 0.01    
CA125 expression Yes vs. no 1.39 (0.79–2.60) 0.25       
Co-expression of mesothelin and CA125 Yes vs. no 3.26 (2.03–5.33) < 0.01     2.22 (1.33–3.77) < 0.01
  1. CI confidence interval, HR hazard ratio, CA125 cancer antigen 125, other carcinomas carcinomas including serous carcinoma, clear cell carcinoma, carcinosarcoma, and mixed carcinoma, FIGO International Federation of Obstetrics and Gynecology